Developer docs
API playgroundTry for free, no card

Search company profiles

Enamine Ltd

Full company profile

uuid0007k6s

Namestring
Enamine Ltd
Legal namestring
ENAMINE Ltd.
Websiteurl
enamine.net
Company typeenum
Private
Founded yearint
1991
Descriptiontext

Enamine Ltd is a privately held contract research organization and chemical supplier founded in 1991, headquartered in Kyiv, Ukraine, with research centers in Frankfurt (Germany) and Wroclaw (Poland), plus distribution offices in Riga (Latvia) and Monmouth Junction, New Jersey (USA). The company specializes in fine organic synthesis and provides chemical building blocks, screening compounds, and integrated drug discovery services to pharmaceutical companies, biotechnology firms, contract research organizations, and academic institutions across more than 20 countries. Its operations are anchored by over 650 skilled chemists and a biology team in which 40% of staff hold PhD degrees.

The company's core technology is the REAL (REadily AccessibLe) Space — a proprietary make-on-demand chemical library spanning trillions of synthetically feasible compounds built over 35 years — complemented by 573,000+ in-stock building blocks, 4.7+ million screening compounds, and 100+ pre-plated compound libraries. EnamineStore, a self-serve e-commerce platform, provides direct catalog access, while Computer-Aided Drug Design (CADD), the REAL Space Navigator (with BioSolveIT), and integrations with drug discovery software (Optibrium StarDrop, Cyclica Ligand Design, ChemAxon MadFast, ZINC/UCSF) embed Enamine's chemical data across the research workflow. The Integrated Drug Discovery (IDD) service platform extends these assets into end-to-end drug discovery programs spanning hit identification, hit-to-lead chemistry, ADME/PK, biology, and preclinical candidate support.

Enamine generates revenue through two principal streams: catalog product sales (building blocks, screening compounds, and pre-plated libraries priced per unit via EnamineStore) and fee-for-service drug discovery collaborations (custom synthesis, FTE chemistry support, IDD programs) with pharmaceutical and biotechnology clients. Long-standing multi-year partnerships with major pharmaceutical companies (Sanofi, Lundbeck, Pfizer, Addex Therapeutics, Actelion Pharmaceuticals) and a growing roster of biotechnology and AI-driven partners (Recursion, Atomwise, Peapod Bio, Nuclide Therapeutics, Variational AI, SyntheticGestalt) indicate a diversified customer base spanning enterprise, mid-market, and academic segments across multiple therapeutic areas including CNS, oncology, infectious disease, and radiopharmaceuticals.

Short descriptiontext

Enamine Ltd is a Ukraine-headquartered contract research organization and chemical supplier providing 573,000+ building blocks, the trillion-scale REAL Space make-on-demand library, and integrated drug discovery services to pharmaceutical, biotechnology, and academic clients across more than 20 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersMonmouth Junction, United States
HQ citystring
Monmouth Junction
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery services, chemical building blocks, compound libraries, custom synthesis, medicinal chemistry
Industry4 codes
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAHAE
Chiral / Asymmetric Synthesis & Complex Chemistry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Drug Discovery Contract Research and Chemical Building-Block Supply
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Compound Sales
TypeOne Time License
Description

Sale of building blocks, screening compounds, and compound libraries through EnamineStore e-commerce platform and catalog sales. Products include over 573,000 building blocks in stock, diverse compound libraries, and custom synthesis options.

enamine.net
2Integrated Drug Discovery Services
TypeProfessional Services
Description

Fee-for-service drug discovery research including synthetic chemistry, medicinal chemistry, ADME/PK, hit-to-lead chemistry, biology services, and FTE chemistry support for pharmaceutical and biotech clients.

enamine.net
3Custom Synthesis
TypeProfessional Services
Description

Custom synthesis services for complex compounds with world-class quality, including late-stage functionalization, flow chemistry, and specialized medicinal chemistry support.

enamine.net
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1Building blocks and screening compounds sold individually with pricing based on quantity and synthesis complexity
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Standard pack sizes for building blocks include 0.1g, 0.25g, 0.5g, 1.0g, and 2.5g. Promotional discounts available for smaller quantities under 2.5 grams. Bulk discounts may be available for Preferred Distributors.

enamine.net
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1REAL (REadily AccessibLe compounds)
Description

Enamine's flagship make-on-demand compound collection comprising trillions of synthetically accessible chemical compounds for drug discovery.

enamine.net
+3 more records
Core offering1 text field

Enamine manufactures and supplies chemical building blocks, screening compounds, fragment libraries, and make-on-demand libraries (REAL Space and xREAL Space) used in early-stage drug discovery. The company delivers contract research services spanning custom synthesis, library synthesis, integrated drug discovery (IDD), computer-aided drug design (CADD), and biology/DMPK assays, serving pharmaceutical, biotechnology, and academic customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Delivered development milestones ahead of schedule with efficient resource use for Nuclide Therapeutics radiotheranostics pipeline
+3 more records
Product overview1 text field

Enamine Ltd is a contract research organization (CRO) specializing in fine organic synthesis and drug discovery services, operating as a platform-plus-modules architecture. The core platform consists of EnamineStore, an e-commerce portal for accessing the company's extensive chemical collections. The main product modules include Building Blocks (573,000+ compounds in stock across multiple specialty categories), REAL Compounds/REAL Space (the world's largest make-on-demand library spanning trillions of compounds), Compound Libraries (100+ pre-plated libraries including AI-enabled, diversity, targeted, and fragment libraries), and Screening Collections. Service modules encompass Integrated Drug Discovery (IDD) for end-to-end drug discovery, Library Synthesis, Custom Synthesis, CADD, Biology Services, FTE Chemistry Support, Hamilton Verso automated storage, UFrag Library, and Hit Follow-up Support. The company maintains research centers in Kyiv (headquarters), Frankfurt, and Wroclaw, with distribution through Enamine LV SIA (EU) and Enamine US Inc. (North America).

Product and service13 records
1Building Blocks Catalog
CategoryChemical building-block supply
Description

On-demand supply of more than 573,000 in-stock building blocks across multiple pack sizes (typically 100 mg–2.5 g) for medicinal chemistry and drug discovery customers worldwide.

2REAL Space Make-on-Demand Compound Library
CategoryMake-on-demand chemical library
Description

Make-on-demand chemical library spanning trillions of accessible structures, designed and selected using EnamineStore, the REAL Space Navigator, and BioSolveIT infiniSee for hit identification and library design.

3xREAL Space Frozen Library
CategoryMake-on-demand chemical library
Description

xREAL Space offers the benefits of REAL Space in a defined, frozen format suitable for routine screening, providing on-demand access to large, design-focused chemistry sets.

4Screening Collections and Pre-Plated Libraries
CategoryPre-plated screening library
Description

More than 100 pre-plated screening collections for high-throughput biology and lead discovery, available alongside custom library design services.

5uFrag Fragment Library
CategoryFragment-based screening library
Description

A fragment-based discovery program offering a low-molecular-weight collection tailored for fragment-based ligand discovery and optimization.

6Custom Synthesis Services
CategoryCustom synthesis CRO
Description

Custom synthesis of non-listed organic molecules and building blocks under defined timelines, supporting medicinal chemistry and analoging programs.

7Library Synthesis Services
CategoryMedicinal-chemistry CRO
Description

Design and synthesis of focused and targeted compound libraries based on customer-specified scaffolds, hypotheses, or AI-generated designs.

8Integrated Drug Discovery (IDD)
CategoryDrug discovery CRO
Description

End-to-end drug discovery service combining medicinal chemistry design, custom synthesis, in-vitro and in-vivo biology, ADME, and PK studies to advance candidates from hit to development candidate.

9Computer-Aided Drug Design (CADD)
CategoryComputational chemistry services
Description

Computational chemistry services covering virtual screening, structure- and ligand-based design, pharmacophore modeling, and AI-driven library design for early-stage discovery projects.

10Biology and DMPK Services
CategoryBiology CRO
Description

In vitro and in vivo biology, pharmacology, and DMPK assay services supporting SAR studies, lead optimization, and preclinical candidate selection within integrated or standalone engagements.

11Hamilton Verso Automated Compound Management
CategoryCompound management service
Description

Automated compound storage and management service built around Hamilton Verso, supporting acquisition, quality control, repacking, and plating of customer compound collections.

12Hit Follow-Up and Lead Optimization Support
CategoryMedicinal-chemistry CRO
Description

Synthetic chemistry support for analoging, SAR generation, and lead optimization, combined with biology feedback to progress screening hits into development-quality leads.

13EnamineStore E-Commerce Platform
CategoryDigital commerce platform
Description

Enamine's online e-commerce platform that lets customers browse, price, and order catalog building blocks, screening collections, and pre-plated libraries directly, with account-management tools for institutional customers.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership29 partners
1Pohang Accelerator Laboratory (PAL)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-13
Description

Collaborative framework for crystallographic fragment screening, combining PAL's public crystallography infrastructure with Enamine's compound libraries and hit-to-lead chemistry services.

enamine.net
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-29
Description

Strategic partnership to advance AI models for drug discovery, combining SyntheticGestalt's molecule-specialized foundation AI model SG4D10B with Enamine's chemical synthesis expertise and compound libraries.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

Joint service for fragment-based lead discovery combining Chemspace's ML-guided hit identification, Enamine's REAL Space and synthetic chemistry, and PSI's crystallographic screening at the Swiss Light Source.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-24
Description

Open-science collaboration to discover PRMT6 inhibitors for Spinal and Bulbar Muscular Atrophy (SBMA) using AI-driven design and synthetic chemistry with open science principles.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-25
Description

Integration of Enamine's xREAL Space into Chemspace platform, enabling researchers worldwide to search and purchase trillions of make-on-demand chemical compounds through a single online source.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-22
Description

Comprehensive collaboration advancing EMUNO's small molecule programs in immuno-oncology aimed at achieving clinical impact for challenging malignancies, supported by EIC Transition Grant.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-16
Description

Collaboration supporting ABX-CRO's translational medicine approach for imaging agents and radiopharmaceuticals through integrated competencies in biology, chemistry, and computational sciences.

8IHI Project LIGAND-AI
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Multinational initiative with 18 partners across nine countries to advance AI-driven drug discovery with €60M+ budget, generating large datasets of protein-ligand interactions and fostering open science.

desertsun.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-02
Description

Strategic collaboration combining Peapod Bio's high-throughput screening technologies with Enamine's extensive small molecule libraries to accelerate hit discovery and drug development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-23
Description

Research collaboration to broaden tools available for Fragment-based Drug Discovery (FBDD) using fluorinated compound libraries.

11CACHE (Critical Assessment of Computational Hit-finding Experiments)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-18
Description

Enamine joined the CACHE Governing Board, serving as primary supplier of compounds for challenges since inception.

enamine.net
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-16
Description

Collaboration to design, build, and test novel DNA-encoded libraries (DEL) combining Chemspace's chemi-informatics, Enamine's REAL design principles, and Orogen's DEL expertise.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-09
Description

Generative-AI driven lead discovery collaboration targeting cerebral perfusion deficits associated with subarachnoid hemorrhage.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-05-26
Description

Selected Pfizer reference compounds made available through Enamine's marketplace and integration capabilities for researchers to explore and purchase.

15Pohang Accelerator Laboratory (PAL)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-30
Description

MOU to advance collaborative drug discovery in fragment-based drug discovery and hit optimization, combining advanced screening technologies with fast-track chemical development.

enamine.net
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-04-25
Description

MOU for cooperation across academic and business domains to strengthen research and scientific exchange in chemical science.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-09
Description

Release of 10 AI-enabled targeted compound libraries comprising over 15,000 newly synthesized compounds designed for 100 key drug targets, combining Recursion's AI/ML platform with Enamine's REAL Space.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Collaboration since 2025 to advance Nuclide's radiotheranostics pipeline for therapy-resistant cancers toward IND-enabling studies and first-in-human clinical trials using Enamine's synthetic chemistry and REAL Space platform.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-12-13
Description

Exclusive partnership establishing world's most comprehensive chemical space exploration platform, superseding the successful REAL concept with access to billions of compounds.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-02-24
Description

Extended multi-year CNS drug discovery collaboration using allosteric modulation-based approaches with integrated medicinal chemistry and ADME/PK capabilities.

21AIDD (Advanced Machine Learning for Innovative Drug Discovery)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-09-24
Description

EU-funded Horizon 2020 project with €3.93M budget to develop next-generation AI and ML models for drug discovery, training 16 PhD students across 15 institutions.

enamine.net
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2019-11-05
Description

Integration of Enamine's REAL Space with Cyclica's AI-driven Ligand Design platform for polypharmacological compound identification from over 11 billion compounds.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2019-06-24
Description

Collaboration for world's first and largest ten billion compound virtual screen for pediatric oncology drug discovery using AI and novel chemistry.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-03-26
Description

Extended multi-year drug discovery collaboration providing screening libraries, hit finding activities, and FTE chemistry support for multiple CNS research programs.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2018-11-19
Description

Integration of REAL Space Search tool into StarDrop software enabling efficient search of over 11 billion readily accessible compounds from within the drug design platform.

26European Molecular Biology Laboratory (EMBL)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-04-25
Description

Collaboration for discovery and development of novel small molecules against EMBL's proprietary anti-cancer targets using library synthesis and medicinal chemistry.

enamine.net
27Actelion Pharmaceuticals
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-01-23
Description

Expanded collaboration in early drug discovery covering cardiovascular, CNS, immunology, infectious diseases, and oncology therapeutic areas.

enamine.net
28UkrOrgSynthesis Ltd (UORSY)
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2016-04-18
Description

Collaboration making combined companies the largest global manufacturer and seller of building blocks with 60,000 products in stock and ~8 million tangible building blocks.

enamine.net
29ChemBridge Corporation and FCH Group
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2016-03-01
Description

Launch of Chem-Space global e-procurement marketplace encompassing over 15 million unique molecular building blocks as world's largest chemicals library.

enamine.net
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct competitor in screening libraries and building blocks for early drug discovery, offering similar catalog and custom synthesis services to pharma/biotech.

2ChemBridge Corporation
TypeDirect peer
Description

Direct competitor in building blocks and screening compound catalogs. Co-founded the Chem-Space marketplace with Enamine in 2016 and has overlapping product lines in molecular building blocks and screening libraries.

TypeDirect peer
Description

Chemical marketplace aggregating building blocks from multiple suppliers, directly competing with EnamineStore for screening compound purchases by pharma and biotech researchers.

TypeDirect peer
Description

Direct competitor in chemical building blocks for drug discovery, offering a deep catalog of screening compounds and custom synthesis services to pharma/biotech customers.

TypeDirect peer
Description

Building block and CDMO competitor with comparable catalog-plus-services model. Supplies pharma with intermediates, building blocks, and custom synthesis at scale.

TypeBroad incumbent
Description

Larger CRO/CDMO incumbent offering end-to-end drug discovery and development services. Competes with Enamine's IDD platform but on a much broader scale across modalities.

TypeDirect peer
Description

Chemical marketplace partner/distributor hosting xREAL Space integration. Operates adjacent marketplace for the same building block and screening compound customer base.

TypeEmerging player
Description

Drug discovery software partner co-developing REAL Space Navigator. Sells cheminformatics tools that access Enamine's catalog — adjacent technology partner rather than pure competitor.

TypeDirect peer
Description

Building block and screening library supplier with overlapping catalog offerings for medicinal chemistry customers, including pre-plated libraries and custom synthesis.

TypeRegional player
Description

Building block supplier with similar catalog and custom synthesis focus; primarily serves European pharma/biotech with comparable small-molecule libraries.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers12 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Enamine Ltd

Drug Discovery Contract Research and Chemical Building-Block Supplyenamine.net

Enamine Ltd is a Ukraine-headquartered contract research organization and chemical supplier providing 573,000+ building blocks, the trillion-scale REAL Space make-on-demand library, and integrated drug discovery services to pharmaceutical, biotechnology, and academic clients across more than 20 countries.

What Enamine Ltd does

Enamine Ltd is a privately held contract research organization and chemical supplier founded in 1991, headquartered in Kyiv, Ukraine, with research centers in Frankfurt (Germany) and Wroclaw (Poland), plus distribution offices in Riga (Latvia) and Monmouth Junction, New Jersey (USA). The company specializes in fine organic synthesis and provides chemical building blocks, screening compounds, and integrated drug discovery services to pharmaceutical companies, biotechnology firms, contract research organizations, and academic institutions across more than 20 countries. Its operations are anchored by over 650 skilled chemists and a biology team in which 40% of staff hold PhD degrees.

The company's core technology is the REAL (REadily AccessibLe) Space — a proprietary make-on-demand chemical library spanning trillions of synthetically feasible compounds built over 35 years — complemented by 573,000+ in-stock building blocks, 4.7+ million screening compounds, and 100+ pre-plated compound libraries. EnamineStore, a self-serve e-commerce platform, provides direct catalog access, while Computer-Aided Drug Design (CADD), the REAL Space Navigator (with BioSolveIT), and integrations with drug discovery software (Optibrium StarDrop, Cyclica Ligand Design, ChemAxon MadFast, ZINC/UCSF) embed Enamine's chemical data across the research workflow. The Integrated Drug Discovery (IDD) service platform extends these assets into end-to-end drug discovery programs spanning hit identification, hit-to-lead chemistry, ADME/PK, biology, and preclinical candidate support.

Enamine generates revenue through two principal streams: catalog product sales (building blocks, screening compounds, and pre-plated libraries priced per unit via EnamineStore) and fee-for-service drug discovery collaborations (custom synthesis, FTE chemistry support, IDD programs) with pharmaceutical and biotechnology clients. Long-standing multi-year partnerships with major pharmaceutical companies (Sanofi, Lundbeck, Pfizer, Addex Therapeutics, Actelion Pharmaceuticals) and a growing roster of biotechnology and AI-driven partners (Recursion, Atomwise, Peapod Bio, Nuclide Therapeutics, Variational AI, SyntheticGestalt) indicate a diversified customer base spanning enterprise, mid-market, and academic segments across multiple therapeutic areas including CNS, oncology, infectious disease, and radiopharmaceuticals.

Enamine Ltd firmographics

Firmographics
Name
Enamine Ltd
Legal name
ENAMINE Ltd.
Website
https://enamine.net
Company type
Private
Founded year
1991
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Enamine Ltd is a Ukraine-headquartered contract research organization and chemical supplier providing 573,000+ building blocks, the trillion-scale REAL Space make-on-demand library, and integrated drug discovery services to pharmaceutical, biotechnology, and academic clients across more than 20 countries.
Ownership category
akta.pro rank

Enamine Ltd industry classification

Industry
Product category
Drug Discovery Contract Research and Chemical Building-Block Supply
NAICS
Pharmaceutical and Medicine Manufacturing (32541)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAHAE
Chiral / Asymmetric Synthesis & Complex Chemistry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Drug discovery services
  • Chemical building blocks
  • Compound libraries
  • Custom synthesis
  • Medicinal chemistry

Where Enamine Ltd is headquartered

Location

Headquarters

HQ city
Monmouth Junction
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Enamine Ltd business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Compound Sales: Sale of building blocks, screening compounds, and compound libraries through EnamineStore e-commerce platform and catalog sales. Products include over 573,000 building blocks in stock, diverse compound libraries, and custom synthesis options.
  2. Integrated Drug Discovery Services: Fee-for-service drug discovery research including synthetic chemistry, medicinal chemistry, ADME/PK, hit-to-lead chemistry, biology services, and FTE chemistry support for pharmaceutical and biotech clients.
  3. Custom Synthesis: Custom synthesis services for complex compounds with world-class quality, including late-stage functionalization, flow chemistry, and specialized medicinal chemistry support.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goBuilding blocks and screening compounds sold individually with pricing based on quantity and synthesis complexity

Go-to-market motion3 records

Distribution channels6 records

Marketing channels7 records

Enamine Ltd product offering

Product offering

Core offering

Enamine manufactures and supplies chemical building blocks, screening compounds, fragment libraries, and make-on-demand libraries (REAL Space and xREAL Space) used in early-stage drug discovery. The company delivers contract research services spanning custom synthesis, library synthesis, integrated drug discovery (IDD), computer-aided drug design (CADD), and biology/DMPK assays, serving pharmaceutical, biotechnology, and academic customers.

Product overview

Enamine Ltd is a contract research organization (CRO) specializing in fine organic synthesis and drug discovery services, operating as a platform-plus-modules architecture. The core platform consists of EnamineStore, an e-commerce portal for accessing the company's extensive chemical collections. The main product modules include Building Blocks (573,000+ compounds in stock across multiple specialty categories), REAL Compounds/REAL Space (the world's largest make-on-demand library spanning trillions of compounds), Compound Libraries (100+ pre-plated libraries including AI-enabled, diversity, targeted, and fragment libraries), and Screening Collections. Service modules encompass Integrated Drug Discovery (IDD) for end-to-end drug discovery, Library Synthesis, Custom Synthesis, CADD, Biology Services, FTE Chemistry Support, Hamilton Verso automated storage, UFrag Library, and Hit Follow-up Support. The company maintains research centers in Kyiv (headquarters), Frankfurt, and Wroclaw, with distribution through Enamine LV SIA (EU) and Enamine US Inc. (North America).

Differentiator

Problem solved

Functional benefit

Brands

  • REAL (REadily AccessibLe compounds): Enamine's flagship make-on-demand compound collection comprising trillions of synthetically accessible chemical compounds for drug discovery.
  • xREAL Space
  • MADE Building Blocks
  • Integrated Drug Discovery (IDD)

Products and services

  • Building Blocks Catalog On-demand supply of more than 573,000 in-stock building blocks across multiple pack sizes (typically 100 mg–2.5 g) for medicinal chemistry and drug discovery customers worldwide.
  • REAL Space Make-on-Demand Compound Library Make-on-demand chemical library spanning trillions of accessible structures, designed and selected using EnamineStore, the REAL Space Navigator, and BioSolveIT infiniSee for hit identification and library design.
  • xREAL Space Frozen Library xREAL Space offers the benefits of REAL Space in a defined, frozen format suitable for routine screening, providing on-demand access to large, design-focused chemistry sets.
  • Screening Collections and Pre-Plated Libraries More than 100 pre-plated screening collections for high-throughput biology and lead discovery, available alongside custom library design services.
  • uFrag Fragment Library A fragment-based discovery program offering a low-molecular-weight collection tailored for fragment-based ligand discovery and optimization.
  • Custom Synthesis Services Custom synthesis of non-listed organic molecules and building blocks under defined timelines, supporting medicinal chemistry and analoging programs.
  • Library Synthesis Services Design and synthesis of focused and targeted compound libraries based on customer-specified scaffolds, hypotheses, or AI-generated designs.
  • Integrated Drug Discovery (IDD) End-to-end drug discovery service combining medicinal chemistry design, custom synthesis, in-vitro and in-vivo biology, ADME, and PK studies to advance candidates from hit to development candidate.
  • Computer-Aided Drug Design (CADD) Computational chemistry services covering virtual screening, structure- and ligand-based design, pharmacophore modeling, and AI-driven library design for early-stage discovery projects.
  • Biology and DMPK Services In vitro and in vivo biology, pharmacology, and DMPK assay services supporting SAR studies, lead optimization, and preclinical candidate selection within integrated or standalone engagements.
  • Hamilton Verso Automated Compound Management Automated compound storage and management service built around Hamilton Verso, supporting acquisition, quality control, repacking, and plating of customer compound collections.
  • Hit Follow-Up and Lead Optimization Support Synthetic chemistry support for analoging, SAR generation, and lead optimization, combined with biology feedback to progress screening hits into development-quality leads.
  • EnamineStore E-Commerce Platform Enamine's online e-commerce platform that lets customers browse, price, and order catalog building blocks, screening collections, and pre-plated libraries directly, with account-management tools for institutional customers.

Quantifiable outcome

  • Delivered development milestones ahead of schedule with efficient resource use for Nuclide Therapeutics radiotheranostics pipeline
  • +3 more outcomes

Companies that use Enamine Ltd

Customer profile

Named customers12 records

Segments4 records

Ideal customer profiles3 records

Enamine Ltd technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability5 records

Feature6 records

Enamine Ltd partnerships and signals

Strategic signal

Partnerships

29 partnerships are on record, tiered core and minor.

  • Pohang Accelerator Laboratory (PAL)coreStrategic or Co-development Partner · 13 May 2026Collaborative framework for crystallographic fragment screening, combining PAL's public crystallography infrastructure with Enamine's compound libraries and hit-to-lead chemistry services.
  • SyntheticGestaltcoreStrategic or Co-development Partner · 29 April 2026Strategic partnership to advance AI models for drug discovery, combining SyntheticGestalt's molecule-specialized foundation AI model SG4D10B with Enamine's chemical synthesis expertise and compound libraries.
  • Chemspace and Paul Scherrer InstitutecoreStrategic or Co-development Partner · 7 April 2026Joint service for fragment-based lead discovery combining Chemspace's ML-guided hit identification, Enamine's REAL Space and synthetic chemistry, and PSI's crystallographic screening at the Swiss Light Source.
  • Agora Open Science Trust and Variational AIcoreStrategic or Co-development Partner · 24 March 2026Open-science collaboration to discover PRMT6 inhibitors for Spinal and Bulbar Muscular Atrophy (SBMA) using AI-driven design and synthetic chemistry with open science principles.
  • ChemspacecoreTechnology or Integration · 25 February 2026Integration of Enamine's xREAL Space into Chemspace platform, enabling researchers worldwide to search and purchase trillions of make-on-demand chemical compounds through a single online source.
  • EMUNO TherapeuticscoreStrategic or Co-development Partner · 22 January 2026Comprehensive collaboration advancing EMUNO's small molecule programs in immuno-oncology aimed at achieving clinical impact for challenging malignancies, supported by EIC Transition Grant.
  • ABX-CROcoreStrategic or Co-development Partner · 16 January 2026Collaboration supporting ABX-CRO's translational medicine approach for imaging agents and radiopharmaceuticals through integrated competencies in biology, chemistry, and computational sciences.
  • IHI Project LIGAND-AIcoreStrategic or Co-development Partner · 1 January 2026Multinational initiative with 18 partners across nine countries to advance AI-driven drug discovery with €60M+ budget, generating large datasets of protein-ligand interactions and fostering open science.
  • Peapod Bio Inc.coreStrategic or Co-development Partner · 2 December 2025Strategic collaboration combining Peapod Bio's high-throughput screening technologies with Enamine's extensive small molecule libraries to accelerate hit discovery and drug development.
  • Institute of Cancer Research (ICR), LondoncoreStrategic or Co-development Partner · 23 September 2025Research collaboration to broaden tools available for Fragment-based Drug Discovery (FBDD) using fluorinated compound libraries.
  • CACHE (Critical Assessment of Computational Hit-finding Experiments)coreStrategic or Co-development Partner · 18 September 2025Enamine joined the CACHE Governing Board, serving as primary supplier of compounds for challenges since inception.
  • Orogen Therapeutics and ChemspacecoreStrategic or Co-development Partner · 16 July 2025Collaboration to design, build, and test novel DNA-encoded libraries (DEL) combining Chemspace's chemi-informatics, Enamine's REAL design principles, and Orogen's DEL expertise.
  • Qanatpharma, Zuse Institute Berlin, and Proteros biostructurescoreStrategic or Co-development Partner · 9 July 2025Generative-AI driven lead discovery collaboration targeting cerebral perfusion deficits associated with subarachnoid hemorrhage.
  • PfizerminorChannel Partner/ Reseller/ Distributor · 26 May 2025Selected Pfizer reference compounds made available through Enamine's marketplace and integration capabilities for researchers to explore and purchase.
  • Pohang Accelerator Laboratory (PAL)coreStrategic or Co-development Partner · 30 April 2025MOU to advance collaborative drug discovery in fragment-based drug discovery and hit optimization, combining advanced screening technologies with fast-track chemical development.
  • Korean Chemical Society (KCS)minorStrategic or Co-development Partner · 25 April 2025MOU for cooperation across academic and business domains to strengthen research and scientific exchange in chemical science.
  • RecursioncoreStrategic or Co-development Partner · 9 April 2025Release of 10 AI-enabled targeted compound libraries comprising over 15,000 newly synthesized compounds designed for 100 key drug targets, combining Recursion's AI/ML platform with Enamine's REAL Space.
  • Nuclide TherapeuticscoreStrategic or Co-development Partner · 1 January 2025Collaboration since 2025 to advance Nuclide's radiotheranostics pipeline for therapy-resistant cancers toward IND-enabling studies and first-in-human clinical trials using Enamine's synthetic chemistry and REAL Space platform.
  • BioSolveITcoreTechnology or Integration · 13 December 2023Exclusive partnership establishing world's most comprehensive chemical space exploration platform, superseding the successful REAL concept with access to billions of compounds.
  • Addex TherapeuticscoreStrategic or Co-development Partner · 24 February 2021Extended multi-year CNS drug discovery collaboration using allosteric modulation-based approaches with integrated medicinal chemistry and ADME/PK capabilities.
  • AIDD (Advanced Machine Learning for Innovative Drug Discovery)coreStrategic or Co-development Partner · 24 September 2020EU-funded Horizon 2020 project with €3.93M budget to develop next-generation AI and ML models for drug discovery, training 16 PhD students across 15 institutions.
  • CyclicacoreTechnology or Integration · 5 November 2019Integration of Enamine's REAL Space with Cyclica's AI-driven Ligand Design platform for polypharmacological compound identification from over 11 billion compounds.
  • AtomwisecoreTechnology or Integration · 24 June 2019Collaboration for world's first and largest ten billion compound virtual screen for pediatric oncology drug discovery using AI and novel chemistry.
  • LundbeckcoreStrategic or Co-development Partner · 26 March 2019Extended multi-year drug discovery collaboration providing screening libraries, hit finding activities, and FTE chemistry support for multiple CNS research programs.
  • OptibriumcoreTechnology or Integration · 19 November 2018Integration of REAL Space Search tool into StarDrop software enabling efficient search of over 11 billion readily accessible compounds from within the drug design platform.
  • European Molecular Biology Laboratory (EMBL)coreStrategic or Co-development Partner · 25 April 2017Collaboration for discovery and development of novel small molecules against EMBL's proprietary anti-cancer targets using library synthesis and medicinal chemistry.
  • Actelion PharmaceuticalscoreStrategic or Co-development Partner · 23 January 2017Expanded collaboration in early drug discovery covering cardiovascular, CNS, immunology, infectious diseases, and oncology therapeutic areas.
  • UkrOrgSynthesis Ltd (UORSY)coreChannel Partner/ Reseller/ Distributor · 18 April 2016Collaboration making combined companies the largest global manufacturer and seller of building blocks with 60,000 products in stock and ~8 million tangible building blocks.
  • ChemBridge Corporation and FCH GroupcoreChannel Partner/ Reseller/ Distributor · 1 March 2016Launch of Chem-Space global e-procurement marketplace encompassing over 15 million unique molecular building blocks as world's largest chemicals library.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Enamine Ltd competitors and assessment

Company assessment

Direct peers

  • Life Chemicals: Direct competitor in screening libraries and building blocks for early drug discovery, offering similar catalog and custom synthesis services to pharma/biotech.
  • ChemBridge Corporation: Direct competitor in building blocks and screening compound catalogs. Co-founded the Chem-Space marketplace with Enamine in 2016 and has overlapping product lines in molecular building blocks and screening libraries.
  • MolPort: Chemical marketplace aggregating building blocks from multiple suppliers, directly competing with EnamineStore for screening compound purchases by pharma and biotech researchers.
  • Combi-Blocks: Direct competitor in chemical building blocks for drug discovery, offering a deep catalog of screening compounds and custom synthesis services to pharma/biotech customers.
  • PharmaBlock Sciences: Building block and CDMO competitor with comparable catalog-plus-services model. Supplies pharma with intermediates, building blocks, and custom synthesis at scale.
  • ChemSpace: Chemical marketplace partner/distributor hosting xREAL Space integration. Operates adjacent marketplace for the same building block and screening compound customer base.
  • Asinex: Building block and screening library supplier with overlapping catalog offerings for medicinal chemistry customers, including pre-plated libraries and custom synthesis.

Broad incumbents

  • WuXi AppTec: Larger CRO/CDMO incumbent offering end-to-end drug discovery and development services. Competes with Enamine's IDD platform but on a much broader scale across modalities.

Emerging players

  • BioSolveIT: Drug discovery software partner co-developing REAL Space Navigator. Sells cheminformatics tools that access Enamine's catalog — adjacent technology partner rather than pure competitor.

Regional players

  • Vitas-M Chemical: Building block supplier with similar catalog and custom synthesis focus; primarily serves European pharma/biotech with comparable small-molecule libraries.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

Enamine Ltd social profiles

Digital presence

Enamine Ltd financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Enamine Ltd leadership team

Management profile

Number of profiles

Profiles7 records

Enamine Ltd subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Enamine Ltd funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Enamine Ltd M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Enamine Ltd

What does Enamine Ltd do?

Enamine manufactures and supplies chemical building blocks, screening compounds, fragment libraries, and make-on-demand libraries (REAL Space and xREAL Space) used in early-stage drug discovery. The company delivers contract research services spanning custom synthesis, library synthesis, integrated drug discovery (IDD), computer-aided drug design (CADD), and biology/DMPK assays, serving pharmaceutical, biotechnology, and academic customers.

Is Enamine Ltd a public or private company?

Enamine Ltd is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Enamine Ltd founded?

Enamine Ltd was founded in 1991. It employs 1,001 to 5,000 people.

Where is Enamine Ltd based?

Enamine Ltd is headquartered in Monmouth Junction, United States, in the North America region.

How does Enamine Ltd make money?

Three revenue lines are on record. Compound Sales are the primary driver. The others are integrated Drug Discovery Services and custom Synthesis.

Who are Enamine Ltd's main competitors?

Direct peers on record are Life Chemicals, ChemBridge Corporation, MolPort, Combi-Blocks, PharmaBlock Sciences, ChemSpace and Asinex. WuXi AppTec is listed as a broad incumbent. BioSolveIT is listed as an emerging player. Vitas-M Chemical is listed as a regional player.

Does Enamine Ltd have an API?

No public API is recorded for Enamine Ltd.

What industry is Enamine Ltd in?

Enamine Ltd's product category is Drug Discovery Contract Research and Chemical Building-Block Supply. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAAAIAL, Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries). Its NAICS code is 32541 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrtimesEnamineとSyntheticGestalt、世界最大規模のAI創薬データ構築に向けた協業を発表SyntheticGestalt and Enamine announced a partnership to build the world's largest in vitro validated AI-driven chemical data ecosystem. The collaboration will analyze 100 protein targets and generate hundreds of thousands of data points, with the dataset planned for public release in 2027.EIN PresswireSyntheticGestalt and Enamine Build the World’s Largest Experimentally Validated AI-driven Chemical Data EcosystemSyntheticGestalt and Enamine announced a collaboration to build the world's largest experimentally validated AI-driven chemical data ecosystem. SyntheticGestalt will analyze 100 protein targets and prioritize compounds for synthesis, while Enamine provides its B-REAL platform. The dataset is expected to be released in 2027.EIN PresswireANTARES project launch: Artificial Intelligence aims to speed up the search for new antibacterialsThe ANTARES project, a German public-private partnership, launched on July 23, 2026, to use AI models to identify novel antibiotics. Funded by €1.18 million from the Federal Ministry of Research, Technology and Space, it involves Fraunhofer ITMP, HZI, and Enamine. The models will be trained on public datasets and iteratively improved with high-throughput testing.EnamineNews & Press ReleasesThe provided text is a collection of multiple unrelated press releases and news updates rather than a single cohesive article. The content covers various strategic collaborations, platform integrations, and organizational announcements involving Enamine, Chemspace, and other entities in the drug discovery sector throughout 2025 and 2026.EIN Presswire'Leveraging Public Infrastructure for Private Innovation: Enamine and PAL Align'Enamine and Pohang Accelerator Laboratory (PAL) announced a partnership for crystallographic fragment screening, combining PAL's public research facilities with Enamine's compound libraries. The collaboration aims to lower barriers for academic and industry researchers, offering access to refined fragment libraries and automated workflows. It also supports rapid hit-to-lead progression.EIN PresswireEnamine Joins Agora Open Science Trust and Variational AI to Advance Open-Science Discovery of PRMT6 InhibitorsEnamine, a Kyiv-based drug discovery CRO, announced its participation in an open-science collaboration with Variational AI and Agora Open Science Trust to discover novel small-molecule inhibitors targeting PRMT6 for Spinal and Bulbar Muscular Atrophy (SBMA), a rare neuromuscular disorder with no approved disease-modifying treatments. The initiative integrates Variational AI's Enki™ generative AI platform with Enamine's synthetically validated xREAL chemical space and rapid synthesis capabilities within a fully transparent design–make–test–analyze framework, with all molecular data and progress made publicly available. The partnership includes additional network collaborators such as the Structural Genomics Consortium, University Health Network, University of Oxford, and Charles River Laboratories.PharmiWeb.comPeapod Bio Inc. and Enamine Ltd. Announce Strategic CollaborationPeapod Bio Inc. and Enamine Ltd. announced a strategic collaboration to combine Peapod Bio's assay development and high-throughput screening technologies with Enamine's collection of nearly five million small molecule compounds. The partnership enables Peapod Bio to offer fully integrated screening campaigns while extending Enamine's compound libraries to new discovery platforms, including Peapod Bio's proprietary affinity selection mass spectrometry platform. Both companies describe the collaboration as complementary, aimed at accelerating hit discovery and helping researchers identify high-value starting points for drug development.MorningstarEnamine contributes to the discovery of promising broad-spectrum coronavirus antiviralEnamine, a chemistry and R&D services company, contributed to the discovery of ASAP-0017445, a promising broad-spectrum coronavirus antiviral pre-clinical candidate developed through the open-science COVID Moonshot and ASAP consortium. The drug candidate was nominated by the Drugs for Neglected Diseases initiative (DNDi) as highly effective, with Enamine playing a pivotal role in generating over 2,000 compounds and performing ADME tests to accelerate the discovery cycle. All generated compounds are now available from Enamine's catalogue to support future pandemic resilience efforts.PharmiWeb.comEnamine contributes to the discovery of promising broad-spectrum coronavirus antiviralEnamine contributed to the discovery of ASAP-0017445, a promising broad-spectrum coronavirus antiviral pre-clinical candidate, by synthesizing over 2,000 new compounds for the open-science COVID Moonshot and ASAP consortium. The candidate was nominated by the Drugs for Neglected Diseases initiative (DNDi) as highly effective and is designed as a direct-to-generic treatment for future pandemics. All generated compounds are now available from Enamine's catalogue to support ongoing research.EnamineOrogen Therapeutics Announces a Strategic Collaboration with Enamine and Chemspace to Enable Unique REAL-Driven DNA-Encoded Small Molecule LibrariesOrogen Therapeutics, Chemspace, and Enamine announced a strategic collaboration to design, build, and test novel DNA-encoded libraries (DEL) leveraging Chemspace's chemi-informatics and Enamine's REAL design principles. Under the agreement, Orogen will screen pilot DELs against biological targets while the partners synthesize and validate the libraries to enhance drug discovery capabilities for immuno-inflammatory disorders and oncology.